Technologies
This technology decreases the infiltration of suppressive immune cells at the tumor site by blocking IL-8 and/or its receptors, potentially improving treatment outcomes for prostate cancer.
Prostate cancer is among the most common cancers in men worldwide, with approximately 900,000 cases and over 250,000 deaths annually. More aggressive forms of prostate cancer are commonly treated using androgen deprivation therapy (ADT), sometimes in parallel with other treatments such as chemotherapy or immunotherapy. Patients treated with ADT typically have elevated inflammatory biomarkers, such as IL-8, which recruit suppressive immune cells to the tumor microenvironment leading to poor treatment outcomes. There is a need for therapeutics that minimize these immunosuppressive effects, in order to boost immune response to cancer cells and maximize treatment efficacy.
This technology describes a method for treating prostate cancer by blocking IL-8 and its related receptors. Cancer cells often exhibit increased expression of IL-8. By blocking this chemokine and/or its receptors, recruitment of suppressive immune cells to the tumor microenvironment is significantly decreased. Therefore, this technology can boost immune response to cancer cells, enhance the efficacy of ADT and immunotherapy, and may lead to improved patient outcomes.
This technology has been validated in human prostate cancer cells and related mouse models of prostate cancer.
IR CU19210
Licensing Contact: Joan Martinez